Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 7/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4155695 | 0.92 | TACR1 (0.42) | TACR1MCL1ALDH1A1CTDSP1SLC6A9 | |
| SCHEMBL3644830 | 0.91 | TACR1 (0.44) | TACR1SLC6A9UTS2R | |
| SCHEMBL3644833 | 0.91 | TACR1 (0.44) | TACR1SLC6A9UTS2R | |
| SCHEMBL3648595 | 0.91 | TACR1 (0.44) | TACR1SLC6A9UTS2R | |
| SCHEMBL3642184 | 0.89 | TACR1 (0.43) | TACR1SLC6A9UTS2R | |
| SCHEMBL3648189 | 0.88 | TACR1 (0.40) | TACR1MC4R | |
| SCHEMBL3640605 | 0.86 | PTGDR2 (0.41) | TACR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3645996 | 0.86 | TACR1 (0.44) | TACR1SLC6A9UTS2R | |
| SCHEMBL3645993 | 0.86 | TACR1 (0.44) | TACR1SLC6A9UTS2R | |
| SCHEMBL3645573 | 0.86 | PTGIR (0.43) | TACR1SLC6A9UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101801918-A | Monoamide derivatives as orexin receptor antagonists | HOFFMANN LA ROCHE | 2010-08-11 | — | — | CN | disclosed |
| EP-2185503-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009016087-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016087-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036422-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036422-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036422-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036422-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, MTNR1A | TACR1 78/4885MCL1 4690/4885ALDH1A1 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.